TY - JOUR
T1 - World Heart Federation roadmap on atrial fibrillation – A 2020 update
AU - Freedman, Ben
AU - Hindricks, Gerhard
AU - Banerjee, Amitava
AU - Baranchuk, Adrian
AU - Ching, Chi Keong
AU - Du, Xin
AU - Fitzsimons, Donna
AU - Healey, Jeff S.
AU - Ikeda, Takanori
AU - Lobban, Trudie C.A.
AU - Mbakwem, Amam
AU - Narasimhan, Calambur
AU - Neubeck, Lis
AU - Noseworthy, Peter
AU - Philbin, Daniel M.
AU - Pinto, Fausto J.
AU - Rwebembera, Joselyn
AU - Schnabel, Renate B.
AU - Svendsen, Jesper Hastrup
AU - Aguinaga, Luis
AU - Arbelo, Elena
AU - Böhm, Michael
AU - Farhan, Hasan Ali
AU - Richard Hobbs, F. D.
AU - Martínez-Rubio, Antoni
AU - Militello, Claudio
AU - Naik, Nitish
AU - Noubiap, Jean Jacques
AU - Perel, Pablo
AU - Piñeiro, Daniel José
AU - Ribeiro, Antonio Luiz
AU - Stepinska, Janina
N1 - Funding Information:
Ben Freedman reports prior fees and advisory board honoraria from Bayer Pharma AG, Boehringer Ingel-heim, Daiichi-Sankyo, Omron and Pfizer/BMS, loan devices from Alivecor, and grants to the institution for investigator-initiated studies from BMS/Pfizer, unrelated to the current work. Jeff Healey has held research grants and received speaking fees from BMS/Pfizer, Bayer, Servier, Medtronic, Boston Scientific, Abbott, ARCA biopharma, Cipher pharma, and Myokardia. Lis Neubeck has received honoraria from Pfizer BMS and Daiichi Sankyo (<£2000). Renate Schnabel has received lecture fees from BMS/Pfizer outside this work. Jes-per Hastrup Svendsen reports grants, personal fees, and other from Medtronic and grants from Gilead. Isabel Arbelo has received speaker fees from Biosense Webster. FD Richard Hobbs has received occasional fees and or travel expenses reimbursed in the past five years for consultancy, speaking, or advisory meetings from BI and Bayer. Janina Stepinska has received research grants from Bayer and Sanofi; consulting or lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, and Servier. Antoni Martínez-Rubio has participated in scientific advisory boards or research projects financed by Bayer, Boehringer Ingelheim, Daichii-Sankyo, and Pfizer.
Publisher Copyright:
© 2021 The Author(s).
PY - 2021/5/27
Y1 - 2021/5/27
N2 - The World Heart Federation (WHF) commenced a Roadmap initiative in 2015 to reduce the global burden of cardiovascular disease and resultant burgeoning of healthcare costs. Roadmaps provide a blueprint for implementation of priority solutions for the principal cardiovascular diseases leading to death and disability. Atrial fibrillation (AF) is one of these conditions and is an increasing problem due to ageing of the world’s population and an increase in cardiovascular risk factors that predispose to AF. The goal of the AF roadmap was to provide guidance on priority interventions that are feasible in multiple countries, and to identify roadblocks and potential strategies to overcome them. Since publication of the AF Roadmap in 2017, there have been many technological advances including devices and artificial intelligence for identification and prediction of unknown AF, better methods to achieve rhythm control, and widespread uptake of smartphones and apps that could facilitate new approaches to healthcare delivery and increasing community AF awareness. In addition, the World Health Organisation added the non-vitamin K antagonist oral anticoagulants (NOACs) to the Essential Medicines List, making it possible to increase advocacy for their widespread adoption as therapy to prevent stroke. These advances motivated the WHF to commission a 2020 AF Roadmap update. Three years after the original Roadmap publication, the identified barriers and solutions were judged still relevant, and progress has been slow. This 2020 Roadmap update reviews the significant changes since 2017 and identifies priority areas for achieving the goals of reducing death and disability related to AF, particularly targeted at low-middle income countries. These include advocacy to increase appreciation of the scope of the problem; plugging gaps in guideline management and prevention through physician education, increasing patient health literacy, and novel ways to increase access to integrated healthcare including mHealth and digital transformations; and greater emphasis on achieving practical solutions to national and regional entrenched barriers. Despite the advances reviewed in this update, the task will not be easy, but the health rewards of implementing solutions that are both innovative and practical will be great.
AB - The World Heart Federation (WHF) commenced a Roadmap initiative in 2015 to reduce the global burden of cardiovascular disease and resultant burgeoning of healthcare costs. Roadmaps provide a blueprint for implementation of priority solutions for the principal cardiovascular diseases leading to death and disability. Atrial fibrillation (AF) is one of these conditions and is an increasing problem due to ageing of the world’s population and an increase in cardiovascular risk factors that predispose to AF. The goal of the AF roadmap was to provide guidance on priority interventions that are feasible in multiple countries, and to identify roadblocks and potential strategies to overcome them. Since publication of the AF Roadmap in 2017, there have been many technological advances including devices and artificial intelligence for identification and prediction of unknown AF, better methods to achieve rhythm control, and widespread uptake of smartphones and apps that could facilitate new approaches to healthcare delivery and increasing community AF awareness. In addition, the World Health Organisation added the non-vitamin K antagonist oral anticoagulants (NOACs) to the Essential Medicines List, making it possible to increase advocacy for their widespread adoption as therapy to prevent stroke. These advances motivated the WHF to commission a 2020 AF Roadmap update. Three years after the original Roadmap publication, the identified barriers and solutions were judged still relevant, and progress has been slow. This 2020 Roadmap update reviews the significant changes since 2017 and identifies priority areas for achieving the goals of reducing death and disability related to AF, particularly targeted at low-middle income countries. These include advocacy to increase appreciation of the scope of the problem; plugging gaps in guideline management and prevention through physician education, increasing patient health literacy, and novel ways to increase access to integrated healthcare including mHealth and digital transformations; and greater emphasis on achieving practical solutions to national and regional entrenched barriers. Despite the advances reviewed in this update, the task will not be easy, but the health rewards of implementing solutions that are both innovative and practical will be great.
KW - AF
KW - Atrial fibrillation
KW - Cardiology
KW - Digital technology
KW - NOACs
KW - WHF
UR - http://www.scopus.com/inward/record.url?scp=85108100126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108100126&partnerID=8YFLogxK
U2 - 10.5334/GH.1023
DO - 10.5334/GH.1023
M3 - Review article
C2 - 34211827
AN - SCOPUS:85108100126
SN - 2211-8160
VL - 16
JO - CVD Prevention and Control
JF - CVD Prevention and Control
IS - 1
M1 - 41
ER -